TY - JOUR AU - Giordano, S. H. AU - Temin, S. AU - Kirshner, J. J. PY - 2014 DA - 2014// TI - Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline JO - Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.54.0948 DO - 10.1200/JCO.2013.54.0948 ID - Giordano2014 ER - TY - JOUR AU - Slamon, D. J. AU - Leyland-Jones, B. AU - Shak, S. PY - 2001 DA - 2001// TI - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 JO - N Engl J Med VL - 344 UR - https://doi.org/10.1056/NEJM200103153441101 DO - 10.1056/NEJM200103153441101 ID - Slamon2001 ER - TY - JOUR AU - Murphy, C. G. AU - Morris, P. G. PY - 2012 DA - 2012// TI - Recent advances in novel targeted therapies for HER2-positive breast cancer JO - Anti-Cancer Drugs VL - 23 UR - https://doi.org/10.1097/CAD.0b013e328352d292 DO - 10.1097/CAD.0b013e328352d292 ID - Murphy2012 ER - TY - JOUR AU - Oostra, D. R. AU - Macrae, E. R. PY - 2014 DA - 2014// TI - Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer JO - Breast Cancer VL - 6 ID - Oostra2014 ER - TY - JOUR AU - Baselga, J. AU - Swain, S. M. PY - 2009 DA - 2009// TI - Novel anticancer targets:revisiting ERBB2 and discovering ERBB3 JO - NatRev Cancer VL - 9 UR - https://doi.org/10.1038/nrc2656 DO - 10.1038/nrc2656 ID - Baselga2009 ER - TY - JOUR AU - Scheuer, W. AU - Friess, T. AU - Burtscher, H. PY - 2009 DA - 2009// TI - Strongly enhanced antitumor activity of trastuzumaband pertuzumab combination treatment on HER2-positive human xenograft tumor models JO - CancerRes. VL - 69 ID - Scheuer2009 ER - TY - JOUR AU - Metzger-Filho, O. AU - Winer, E. P. AU - Krop, I. PY - 2013 DA - 2013// TI - Pertuzumab: optimizing HER2 blockade JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0518 DO - 10.1158/1078-0432.CCR-13-0518 ID - Metzger-Filho2013 ER - TY - JOUR AU - Cai, Z. AU - Zhang, G. AU - Zhou, Z. PY - 2008 DA - 2008// TI - Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes JO - Oncogene. VL - 27 UR - https://doi.org/10.1038/onc.2008.13 DO - 10.1038/onc.2008.13 ID - Cai2008 ER - TY - JOUR AU - Urruticoechea, A. AU - Rizwanullah, M. AU - Im, S. A. AU - Muñoz, M. PY - 2017 DA - 2017// TI - Randomized phase III trial of Trastuzumab plus Capecitabine with or without Pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast Cancer who experienced disease progression during or after Trastuzumab-based therapy JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.6267 DO - 10.1200/JCO.2016.70.6267 ID - Urruticoechea2017 ER - TY - JOUR AU - Beitsch, P. AU - Whitworth, P. AU - Baron, P. PY - 2017 DA - 2017// TI - Pertuzumab/Trastuzumab/CT versus Trastuzumab/CT therapy for HER2+ breast Cancer: results from the prospective neoadjuvant breast registry symphony trial (NBRST) JO - Ann Surg Oncol VL - 24 UR - https://doi.org/10.1245/s10434-017-5863-x DO - 10.1245/s10434-017-5863-x ID - Beitsch2017 ER - TY - JOUR AU - Gupta, M. AU - Wang, B. AU - Carrothers, T. J. AU - Girish, S. PY - 2013 DA - 2013// TI - Effects of Trastuzumab Emtansine (T-DM1) on QT interval and safety of Pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast Cancer JO - Clin Pharmacol Drug Dev VL - 2 UR - https://doi.org/10.1002/cpdd.9 DO - 10.1002/cpdd.9 ID - Gupta2013 ER - TY - JOUR AU - Higgins, J. P. T. AU - Altman, D. G. AU - Gotzsche, P. C. PY - 2011 DA - 2011// TI - The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials JO - BMJ. VL - 343 UR - https://doi.org/10.1136/bmj.d5928 DO - 10.1136/bmj.d5928 ID - Higgins2011 ER - TY - JOUR AU - Martin, M. AU - Fumoleau, P. AU - Dewar, J. A. AU - Garcia-Saenz, J. A. PY - 2016 DA - 2016// TI - Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw157 DO - 10.1093/annonc/mdw157 ID - Martin2016 ER - TY - JOUR AU - Araki, K. AU - Fukada, I. AU - Yanagi, H. AU - Ito, Y. PY - 2017 DA - 2017// TI - First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer JO - Breast. VL - 35 UR - https://doi.org/10.1016/j.breast.2017.06.015 DO - 10.1016/j.breast.2017.06.015 ID - Araki2017 ER - TY - JOUR AU - Gianni, L. AU - Pienkowski, T. AU - Im, Y. -. H. PY - 2012 DA - 2012// TI - Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70336-9 DO - 10.1016/S1470-2045(11)70336-9 ID - Gianni2012 ER - TY - JOUR AU - Minckwitz, G. AU - Procter, M. AU - Azambuja, E. PY - 2017 DA - 2017// TI - Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast Cancer JO - N Engl J Med VL - 377 ID - Minckwitz2017 ER - TY - JOUR AU - Murthy, R. K. AU - Raghavendra, A. S. AU - Hess, K. R. AU - Ueno, N. T. PY - 2018 DA - 2018// TI - Neoadjuvant Pertuzumab-containing regimens improve pathologic complete response rates in stage II to III HER-2/neu-positive breast Cancer: a retrospective, single institution experience JO - Clin Breast Cancer VL - 18 UR - https://doi.org/10.1016/j.clbc.2018.07.008 DO - 10.1016/j.clbc.2018.07.008 ID - Murthy2018 ER - TY - JOUR AU - Rimawi, M. AU - Ferrero, J. -. M. AU - Haba-Rodriguez, J. PY - 2018 DA - 2018// TI - First-line Trastuzumab plus an aromatase inhibitors, with or without Pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast Cancer (PERTAIN): a randomized, open-label phase II trial JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.76.7863 DO - 10.1200/JCO.2017.76.7863 ID - Rimawi2018 ER - TY - JOUR AU - Swain, S. M. AU - Baselga, J. AU - Kim, S. B. PY - 2015 DA - 2015// TI - Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1413513 DO - 10.1056/NEJMoa1413513 ID - Swain2015 ER - TY - JOUR AU - Krop, I. E. AU - Modi, S. AU - LoRusso, P. M. AU - Elias, A. PY - 2016 DA - 2016// TI - Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer JO - Breast Cancer Res VL - 18 UR - https://doi.org/10.1186/s13058-016-0691-7 DO - 10.1186/s13058-016-0691-7 ID - Krop2016 ER - TY - JOUR AU - Perez, E. A. AU - Barrios, C. AU - Eiermann, W. AU - Ellis, P. PY - 2017 DA - 2017// TI - Trastuzumab Emtansine with or without Pertuzumab versus Trastuzumab plus Taxane for human epidermal growth factor receptor 2–positive, advanced breast Cancer: primary results from the phase III MARIANNE study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.67.4887 DO - 10.1200/JCO.2016.67.4887 ID - Perez2017 ER - TY - JOUR AU - Gianni, L. AU - Bisagni, G. AU - Colleoni, M. AU - Viale, G. PY - 2018 DA - 2018// TI - Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label,phase 2 study JO - Lancet Oncol. VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30001-9 DO - 10.1016/S1470-2045(18)30001-9 ID - Gianni2018 ER - TY - JOUR AU - Foldi, J. AU - Mougalian, S. AU - Silber, A. AU - Pusztai, L. PY - 2017 DA - 2017// TI - Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer JO - Breast Cancer Res Treat VL - 169 UR - https://doi.org/10.1007/s10549-017-4653-2 DO - 10.1007/s10549-017-4653-2 ID - Foldi2017 ER - TY - JOUR AU - Singh, J. C. AU - Mamtani, A. AU - Barrio, A. AU - Dang, C. PY - 2017 DA - 2017// TI - Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with Trastuzumab and Pertuzumab in patients with HER2-positive early stage breast Cancer: a single center experience JO - Oncologist VL - 22 UR - https://doi.org/10.1634/theoncologist.2016-0268 DO - 10.1634/theoncologist.2016-0268 ID - Singh2017 ER - TY - JOUR AU - Tiwari, S. R. AU - Mishra, P. AU - Raska, P. AU - Montero, A. J. PY - 2016 DA - 2016// TI - Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer JO - Breast Cancer Res Treat VL - 158 UR - https://doi.org/10.1007/s10549-016-3866-0 DO - 10.1007/s10549-016-3866-0 ID - Tiwari2016 ER - TY - JOUR AU - Andersson, M. AU - López-Vega, J. M. AU - Petit, T. AU - Perez, E. A. PY - 2017 DA - 2017// TI - Efficacy and safety of Pertuzumab and Trastuzumab administered in a single infusion bag, followed by Vinorelbine: VELVET cohort 2 final results JO - Oncologist. VL - 22 UR - https://doi.org/10.1634/theoncologist.2017-0079 DO - 10.1634/theoncologist.2017-0079 ID - Andersson2017 ER - TY - JOUR AU - Perez, E. A. AU - López-Vega, J. M. AU - Petit, T. AU - Andersson, M. PY - 2016 DA - 2016// TI - Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET cohort 1 final results JO - Breast Cancer Res VL - 18 UR - https://doi.org/10.1186/s13058-016-0773-6 DO - 10.1186/s13058-016-0773-6 ID - Perez2016 ER - TY - JOUR AU - Dang, C. AU - Iyengar, N. AU - Datko, F. AU - Hudis, C. PY - 2015 DA - 2015// TI - Phase II study of paclitaxel given once per week along with Trastuzumab and Pertuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast Cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.57.1745 DO - 10.1200/JCO.2014.57.1745 ID - Dang2015 ER - TY - JOUR AU - Dao, B. D. AU - Ho, H. AU - Quintal, L. N. PY - 2015 DA - 2015// TI - Combination pertuzumab, trastuzumab,and taxane for metastatic breast cancer after first progression: a single institution’s experience JO - J Oncol Pharm Pract VL - 22 UR - https://doi.org/10.1177/1078155215578494 DO - 10.1177/1078155215578494 ID - Dao2015 ER - TY - JOUR AU - Baselga, J. AU - Gelmon, K. A. AU - Verma, S. AU - Gianni, L. PY - 2010 DA - 2010// TI - Phase II trial of Pertuzumab and Trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast Cancer that progressed during prior Trastuzumab therapy JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.24.2024 DO - 10.1200/JCO.2009.24.2024 ID - Baselga2010 ER - TY - JOUR AU - Portera, C. C. AU - Walshe, J. M. AU - Rosing, D. R. AU - Swain, S. M. PY - 2008 DA - 2008// TI - Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive HER2-positive metastatic breast cancer JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-4636 DO - 10.1158/1078-0432.CCR-07-4636 ID - Portera2008 ER - TY - JOUR AU - Robert, N. J. AU - Goertz, H. P. AU - Chopra, P. AU - Antao, V. PY - 2017 DA - 2017// TI - HER2-positive metastatic breast Cancer patients receiving Pertuzumab in a community oncology practice setting:treatment patterns and outcomes JO - Drugs Real World Outcomes VL - 4 UR - https://doi.org/10.1007/s40801-016-0102-5 DO - 10.1007/s40801-016-0102-5 ID - Robert2017 ER - TY - JOUR AU - Placido, S. AU - Giuliano, M. AU - Schettini, F. AU - Arpino, G. PY - 2018 DA - 2018// TI - Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results JO - Breast. VL - 38 UR - https://doi.org/10.1016/j.breast.2017.12.012 DO - 10.1016/j.breast.2017.12.012 ID - Placido2018 ER - TY - JOUR AU - Miller, K. D. AU - Diéras, V. AU - Harbeck, N. AU - Burris, H. A. PY - 2014 DA - 2014// TI - Phase IIa trial of Trastuzumab Emtansine with Pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast Cancer JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.52.6590 DO - 10.1200/JCO.2013.52.6590 ID - Miller2014 ER - TY - JOUR AU - Hussain, N. AU - Said, A. S. A. AU - Khan, Z. PY - 2018 DA - 2018// TI - Safety assessment of neoadjuvant Pertuzumab combined with Trastuzumab in nonmetastatic HER2-positive breast Cancer in postmenopausal elderly women of South Asia JO - Int J Breast Cancer VL - 2018 UR - https://doi.org/10.1155/2018/6106041 DO - 10.1155/2018/6106041 ID - Hussain2018 ER - TY - JOUR AU - Nagayama, A. AU - Hayashida, T. AU - Jinno, H. PY - 2014 DA - 2014// TI - Comparative effectiveness of neoadjuvant therapy for HER2-positive breast Cancer: a network meta-analysis JO - J Natl Cancer Inst VL - 106 UR - https://doi.org/10.1093/jnci/dju203 DO - 10.1093/jnci/dju203 ID - Nagayama2014 ER - TY - JOUR AU - Giuliano, M. AU - Hu, H. AU - Wang, Y. C. AU - Fu, X. AU - Nardone, A. AU - Herrera, S. PY - 2015 DA - 2015// TI - Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2728 DO - 10.1158/1078-0432.CCR-14-2728 ID - Giuliano2015 ER - TY - JOUR AU - Takada, M. AU - Higuchi, T. AU - Tozuka, K. AU - Takei, H. AU - Haruta, M. AU - Watanabe, J. PY - 2013 DA - 2013// TI - Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy JO - BMC Cancer VL - 13 UR - https://doi.org/10.1186/1471-2407-13-241 DO - 10.1186/1471-2407-13-241 ID - Takada2013 ER - TY - JOUR AU - Warren, C. M. AU - Landgraf, R. PY - 2006 DA - 2006// TI - Signaling through ERBB receptors: multiple layers of diversity and control JO - Cell Signal VL - 18 UR - https://doi.org/10.1016/j.cellsig.2005.12.007 DO - 10.1016/j.cellsig.2005.12.007 ID - Warren2006 ER - TY - JOUR AU - Crone, S. A. AU - Negro, A. AU - Trumpp, A. PY - 2003 DA - 2003// TI - Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system JO - Neuron. VL - 37 UR - https://doi.org/10.1016/S0896-6273(02)01128-5 DO - 10.1016/S0896-6273(02)01128-5 ID - Crone2003 ER - TY - JOUR AU - Laux, I. AU - Jain, A. AU - Singh, S. PY - 2006 DA - 2006// TI - Epidermal growth factor receptor dimerization status determines skin toxicity to HER kinase targeted therapies JO - Br J Cancer VL - 94 UR - https://doi.org/10.1038/sj.bjc.6602875 DO - 10.1038/sj.bjc.6602875 ID - Laux2006 ER - TY - JOUR AU - Potter, I. Y. AU - Poumay, Y. AU - Squillace, K. A. PY - 2001 DA - 2001// TI - Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation JO - Exp Cell Res VL - 271 UR - https://doi.org/10.1006/excr.2001.5390 DO - 10.1006/excr.2001.5390 ID - Potter2001 ER - TY - JOUR AU - Zhao, Y. Y. AU - Sawyer, D. R. AU - Baliga, R. R. AU - Opel, D. J. AU - Han, X. AU - Marchionni, M. A. AU - Kelly, R. A. PY - 1998 DA - 1998// TI - Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes JO - J Biol Chem VL - 273 UR - https://doi.org/10.1074/jbc.273.17.10261 DO - 10.1074/jbc.273.17.10261 ID - Zhao1998 ER - TY - JOUR AU - Valachis, A. AU - Nearchou, A. AU - Polyzos, N. P. PY - 2013 DA - 2013// TI - Cardiac toxicity in breast cancer patients treated with dual HER2 blockade JO - Int J Cancer VL - 133 UR - https://doi.org/10.1002/ijc.28234 DO - 10.1002/ijc.28234 ID - Valachis2013 ER -